Insider Selling: Pediatrix Medical Group, Inc. (NYSE:MD) Director Sells 27,600 Shares of Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pediatrix Medical Group Stock Down 4.1 %

NYSE:MD opened at $14.15 on Friday. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock’s 50-day moving average price is $12.53 and its 200-day moving average price is $9.85.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the company earned $0.29 earnings per share. Sell-side analysts predict that Pediatrix Medical Group, Inc. will post 1.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. UBS Group upped their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Jefferies Financial Group lifted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Truist Financial upped their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, Mizuho lifted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $16.10.

Institutional Investors Weigh In On Pediatrix Medical Group

Several institutional investors have recently bought and sold shares of the company. Rubric Capital Management LP boosted its stake in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. grew its stake in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares in the last quarter. Boston Partners grew its stake in Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares in the last quarter. Weiss Asset Management LP lifted its stake in Pediatrix Medical Group by 50.5% in the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after purchasing an additional 306,143 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Pediatrix Medical Group by 639.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after purchasing an additional 251,072 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.